Lung Cancer

Reduce Recurrence in Early-Stage NSCLC

May 05, 2021

Edward S. Kim, MD, highlights the impact of osimertinib in the treatment of patients with EGFR-mutant non–small cell lung cancer, next steps with the agent, and the importance of early genetic testing to provide personalized care.

Investigational Combo Improves PFS in NSCLC Subset

March 28, 2021

First-line treatment with camrelizumab, an investigational PD-1 inhibitor, plus chemotherapy induced robust and durable clinical responses in patients with advanced squamous non–small cell lung cancer.

Poziotinib Is Promising in EGFR Exon 20–Mutant NSCLC Treatment

March 07, 2021

Poziotinib, when given at a daily dose of 16 mg, was found to demonstrate clinically meaningful activity when used in treatment-naïve patients with metastatic non–small cell lung cancer who harbor EGFR exon 20 mutations.